EGFR and neoplasm: The most common activating EGFR mutation based on tumor genotyping was exon 19 deletion (64%), followed by exon 21 L858R (34%) and all patients had EGFR T790M confirmed through tumor (45%) and/or ctDNA analysis (55%), based on local laboratory testing at each participating site.